Patients with hyperuricemia who achieve a serum uric acid level below 6 mg/dL using urate-lowering therapies are less likely to experience renal function decline, according to a study published online ahead of print in the Journal of Rheumatology.
In a study of 16,186 patients with hyperuricemia, Gerald D. Levy, MD, of Kaiser Permanente in Downey, Calif., and colleagues found that those treated with urate-lowering therapies and achieved a serum uric acid lower below 6 mg/dL had a significant 37% decrease in the risk of renal outcomes (a 30% or greater reduction in glomerular filtration rate [GFR] from baseline or progression to dialysis or a GFR of 15 mL/min/1.73 m2 or less.
Enjoying our content?
Thanks for visiting Renal & Urology News. We hope you’re enjoying the latest clinical news, full-length features, case studies, and more.
You’ve viewed {{metering-count}} of {{metering-total}} articles this month. If you wish to read unlimited content, please log in or register below. Registration is free.
{{login-button}} {{register-button}}
Log in to continue reading this article.
Don’t miss out on today’s top content on Renal & Urology News. Register for free and gain unlimited access to:
- Clinical News, with personalized daily picks for you
- Case Studies
- Conference Coverage
- Full-Length Features
- Drug Monographs
- And More
{{login-button}} {{register-button}}
Want to read more?
Please login or register first to view this content.